![[FROM LEFT] Claudia Popp, Olga Tkachenko and Marta Carnielli](https://ds982gbwnvyso.cloudfront.net/Pictures/274x183/4/4/1/441_5m4a4767_toprasymposium2022_day3_20221019_816643.jpg)
HM6: Innovation in regulatory science – The path from data to evidence and the promise to streamline the regulatory lifecycle
There is a global evolution in drug development and RWE policy, increasing contribution of RWD/RWE to clinical evidence generation.
This is member-only content
To read this article, SIGN IN NOW if you are a TOPRA member.
Not a TOPRA member yet?
Join now to get access to:
- Features and specialist articles
- CPD supplements
- Comprehensive archive
Not sure yet? Read one of our free editorials to see what you’re missing out on!
The Organisation for Professionals in Regulatory Affairs
- Issues
- Contact us
- Topics A-Z
- Contributors A-Z
- © 2023 Regulatory Rapporteur